Table 3.

Univariate analysis of the association of treatment system – related characteristics with an unfavourable outcome in 629 cases treated for at least 24 hours

Variable		Total	Death			Other unfavourable
		N	N	OR (95% CI)	p	N	OR (95% CI)	p
Specialty responsible for starting treatment1	pulmonary	579	90	1		76	1
	internal medicine	34	11	2.52 (1.17–5.45)	0.018	3	0.82 (0.24–2.81)	0.75
	general medicine	6	2	3.06 (0.50–18.58)	0.22	61	1.81 (0.18–17.65)	0.61
	other	9	4	3.67 (0.97–13.34)	0.056	0	-	-
Specialty responsible for ending treatment2	pulmonary	531	61	1		67	1
	internal medicine	28	17	18.72 (7.10–49.23)	<0.001	5	5.01 (1.49–16.89)	0.009
	general medicine	47	22	6.92 (3.59–13.34)	<0.001	4	1.15 (0.38–3.44)	0.81
	other	15	6	4.96 (1.66–14.77)	0.004	1	0.75 (0.093–6.11)	0.79
Change of specialty responsible for treatment2	no	530	66	1		71	1
	yes	91	40	5.29 (3.21–8.72)	<0.001	6	0.74 (0.30–1.79)	0.68
Number of cases per year for unit giving initial treatment	1 – 4	36	6	0.91 (0.355–2.34)	0.85	5	1.19 (0.59–2.40)	0.64
	5 – 10	30	46	1.20 (0.46–3.16)	0.71	5	0.67 (0.32–1.43)	0.30
	11 – 29	286	50	0.84 (0.54–1.32)	0.46	33	1.16 (0.59–2.28)	0.67
	30 -	277	50	1		37	1
Number of cases per year for unit responsible for ending treatment	1 – 4	93	33	3.27 (1.83–5.84)	<0.001	15	1.79 (0.89–3.63)	0.11
	5 – 10	38	5	0.80 (0.287–2.207)	0.67	5	0.96 (0.34–2.69)	0.39
	11 – 29	278	35	0.74 (0.44–1.23)	0.24	31	0.79 (0.46–1.36)	0.39
	30 -	220	35	1		29	1
Treatment group	standard treatment A	309	64	1		25	1
	standard treatment B	54	7	0.86 (0.36–2.06)	0.73	19	5.97 (2.92–12.20)	<0.001
	standard treatment C	33	1	0.13 (0.018–0.99)	0.05	6	2.03 (0.76–5.41)	0.16
	standard treatment D	155	24	0.72 (0.43–1.21)	0.28	16	1.22 (0.63–2.38)	0.55
	other combination	9	4	0.56 (0.25–1.25)	0.16	2	5.87 (0.94–36.81)	0.06
	ineffective	69	8	4.58 (1.00–21.01)	0.05	12	2.16 (1.01–4.58)	0.05
Treatment combination	standard (A – D)	548	97	1		66	1
	non-standard	81	11	0.78 (0.38–1.55)	0.62	14	1.46 (0.77–2.77)	0.28
Change in treatment group	no	433	91	1		41	1
	yes	196	17	0.40 (0.23–0.70)	0.001	39	2.05 (1.26–3.31)	0.004
Pause of treatment2	no	464	88	1		37	1
	yes	157	16	0.64 (0.36–1.13)	0.14	42	3.97 (2.42–6.562)	<0.001
Pause during intensive phase2	no	483	91	1		44	1
	yes	134	13	0.58 (0.31–1.082)	0.09	35	3.22 (1.95–5.32)	<0.001
Pause during intensive phase, due to side effect	no	523	97	1		56	1
	yes	106	11	0.59 (0.30–1.16)	0.13	24	2.23 (1.30–3.84)	0.005
Pause during continuation phase	no	481	51	1		50	1
	yes	70	8	1.49 (0.66–3.36)	0.35	22	4.18 (2.299–7.601)	<0.001
	NA (other + ineffective)	78

¹Information missing for one case

²Information missing for 7 – 12 cases

Significant p-values are darkened.